"A Dangerous Precedent" - 3rd FDA Advisor Quits After Controversial Alzheimer's Drug Approval | WHAT REALLY HAPPENED

"A Dangerous Precedent" - 3rd FDA Advisor Quits After Controversial Alzheimer's Drug Approval

While the mainstream media focused on the hope-filled headlines that, for the first time since 2003, the FDA approved Biogen's Aduhelm treatment for Alzheimer's Disease; few, if any, were fully aware of the levels of controversy behind the scenes.

Aside from the scientific uncertainty over whether amyloid plaque treatments are an approach worth continuing...

Despite the dominance of the amyloid hypothesis over the past few decades, evidence that links reductions in plaque levels to improvements in cognition is “thin, at best”, says Jason Karlawish, a geriatrician and co-director of the Penn Memory Center in Philadelphia, Pennsylvania.

“Desperation should drive the funding of science, not drive the way we interpret the science,” he says.

It turns out that despite the fact that not one member of the FDA Advisory Committee voted to approve Aduhelm, the FDA recently approved this Alzheimer therapy anyway, relying on an alternative measure of activity.

As Statnews reports, since the FDA's decision, three members of that FDA Advisory Panel have quit.

Webmaster's Commentary: 

We desperately need approaches to this horrific issue of dementia, which come from classical, morally responsible science, rather than what the drug is apt to make, financially; I am quite sure that since its approval, whether it actually works for dementia victims or not, it will be another huge"cash cow" for Big Pharma.

And what the hell is this "alternative measure of activity" which caused this drug to be approved for Alzheimer patients in the first place?!? Can someone please quantify this for me in plain English?!? I am betting that the straight answer to this question is, "HELL no!!"

Comments

SHARE THIS ARTICLE WITH YOUR SOCIAL MEDIA